Chronic lymphocytic leukaemia recurrent

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
BTK inhibitor 1 substance
BCL-2 inhibitor 1 substance
Phase III: 1 Phase II: 1 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    VENETOCLAX
    2025-524283-38-00 1 country n=456
    Pending

Phase II

1 trial
  • AstraZeneca AB Commercial
    ACALABRUTINIB; VENETOCLAX
    2024-518858-17-00 6 countries 2026 n=63
    Recruiting

Phase I

1 trial
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ubix Therapeutics Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 1
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic 1 Phase III 0
New trials by year
2026
1
← All indication landscapes